"10.1371_journal.pone.0061193","plos one","2013-04-22T00:00:00Z","Jürgen Schymeinsky; Hannah Mayer; Christopher Tomsic; Cornelia Tilp; John D Schuetz; Yunhai Cui; Lutz Wollin; Florian Gantner; Klaus J Erb","Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach a.d. Riss, Germany; Department of Pharmaceutical Sciences, St. Jude Childrens Research Hospital, Memphis, Tennessee, United States of America","Revised and approved the manuscript: JDS YC FG LW. Conceived and designed the experiments: JS YC LW FG KJE. Performed the experiments: JS HM C. Tomsic C. Tilp. Analyzed the data: JS HM C. Tomsic YC LW KJE C. Tilp. Contributed reagents/materials/analysis tools: JDS. Wrote the paper: JS KJE.","The authors have the following interests. JS, HM, C. Tomsic, C. Tilp, YC, LW, FG and KJE are employees of Boehringer-Ingelheim Pharma GmbH & Co KG which is a research-based pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines for humans and animals. Boehringer-Ingelheim Pharma GmbH & Co KG provided funding for the experiments. Roflumilast was resynthesized at Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. A semi-automatic cigarette lighter and smoke generator with an electronic timer was used to control the CS exposure (Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany). There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","04","Jürgen Schymeinsky","JS",9,TRUE,5,3,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
